Latest News

AusperBio will use a significant portion of the proceeds to advance AHB 137, an antisense oligonucleotide therapy for CHB, through its Phase III registrational programme and toward potential commercialisation.

MTRH Chief Executive Officer Dr. Philip Kirwa welcomed the Pfizer delegation and highlighted the importance of partnerships with global pharmaceutical companies in supporting the hospital’s efforts to improve patient care.

Kowa is seeking approval based on results from the pivotal Phase III Mont Blanc and Denali trials.

Photonova Spectra uses the company’s Deep Silicon detector technology to produce high-definition images while providing spectral and spatial imaging capabilities.

Cushing’s syndrome of endogenous origin occurs when the body produces excessive amounts of cortisol and other steroid hormones.

Amyl Therapeutics will expand its laboratory facilities at the LegiaPark life sciences campus in Liège, Belgium, to accommodate its growing research programme.

The Task Force will develop options and recommendations for consideration by the Eightieth World Health Assembly.

Located at El Nasr Mall on Ahmed Oraby Street, the clinic houses more than 20 specialized clinics staffed by experienced medical consultants.

The acquisition will give Lilly access to Merida’s technology for developing biologics that selectively eliminate disease-causing autoantibodies.

Under the agreement, Teva would acquire worldwide rights to Igalmi (dexmedetomidine) sublingual film, a prescription medicine, as well as BXCL501, an investigational therapy.